| Literature DB >> 31671922 |
Valentina Lazzara1, Vincenzo Arizza2, Claudio Luparello3, Manuela Mauro4, Mirella Vazzana5.
Abstract
The fight against cancer represents a great challenge for researchers and, for this reason, the search for new promising drugs to improve cancer treatments has become inevitable. Oceans, due to their wide diversity of marine species and environmental conditions have proven to be precious sources of potential natural drugs with active properties. As an example, in this context several studies performed on sponges, tunicates, mollusks, and soft corals have brought evidence of the interesting biological activities of the molecules derived from these species. Also, echinoderms constitute an important phylum, whose members produce a huge number of compounds with diverse biological activities. In particular, this review is the first attempt to summarize the knowledge about starfishes and their secondary metabolites that exhibited a significant anticancer effect against different human tumor cell lines. For each species of starfish, the extracted molecules, their effects, and mechanisms of action are described.Entities:
Keywords: anti-cancer activity; marine invertebrates; molecular drugs; natural compounds; sea-star
Mesh:
Substances:
Year: 2019 PMID: 31671922 PMCID: PMC6891385 DOI: 10.3390/md17110617
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Taxonomy of starfishes and the extracted molecules evaluated for their biological activities
| Species | Bioactive Molecules |
|---|---|
|
| |
|
| Steroids: Astropectenols A–D |
|
| Asterosaponins: Astrosteriosides A–D; |
|
| Polyhydroxysteroidal glycosides: Hesperuside A–C |
|
| |
|
| (22E,24ξ)-26,27-bisnor-24-methyl-5α-cholest-22-en 3β,5,6β,15α,25-pentol 25-O-sulfate |
|
| |
|
| Cerebrosides |
|
| Asterosaponins: Leptasteriosides A–F |
|
| Lethasteriosides A, B |
|
| |
|
| Luzonicoside A, Luzonicoside D |
|
| Leviusculoside G |
|
| |
|
| Plancitoxin protein |
|
| |
|
| Archasterosides A, B |
|
| |
|
| (25S)-5α-cholestane-3β,6α,7α,8,15α,16β-hexahydroxyl-26-O-14′Z-eicosenoate |
|
| |
|
| Steroidal biglycosides: Cariniferosides A–F |
|
| |
| Hippasteriosides A–D | |
|
| |
|
| Certonardosterols |
|
| Glycosphingolipids: Ophidiacerebrosides |
|
| |
|
| Polyhydroxysteroidal glycosides: Anthenoside A, Anthenosides B–K |
|
| Anthenosides S1–S6 |
|
| Anthenosides E, G, J, K, S1, S4, S6 |
|
| Granulatosides D and E, Linckoside L4, Echinasteroside B, Echinasterosides C, E and F, desulfated Echinasteroside A, 22,23-Dihydroechinasteroside A, desulfated Echinasteroside B, Linckoside B, Linckoside E, Linckoside F, Laeviuscoloside D, Granulatoside A, Steroid Heptaol |
|
| Asterosaponins: Novaeguinosides I and II, Regularoside B |
|
| Pentacerosides A and B |
Figure 1Acanthaster planci [19]. © Craig Howe (CC BY-NC-ND).
Figure 2Anthenea aspera [28].
Figure 3Archaster typicus [31]. © budak. Some rights reserved (CC-BY-NC).
Figure 4Asterias amurensis [34].
Figure 5Asterina pectinifera [40]. © Alexander Semenov.
Figure 6Asteropsis carinifera [49]. © P. Bourjon.
Figure 7Astropecten polyacanthus [52]. © Chaloklum Diving CC-BY-3.0 (https://commons.wikimedia.org).
Figure 8Astropecten monacanthus [55].
Figure 9Choriaster granulatus [64]. © Mark & Marta Bockstael-Rubio (https://www.jungledragon.com).
Figure 10Craspidaster Hesperus [67]. © budak, Some Right Reserved (CC BY-NC).
Figure 11Ctenodiscus crispatus [69]. © Rick (https://www.flickr.com).
Figure 12Culcita novaeguineae [71]. © Western Australian Museum Collections (CC BY 4.0).
Figure 13Echinaster luzonicus [79]. © Bernard Dupont (CC-BY-SA-2.0).
Figure 14Henricia leviuscula [81]. © Christopher Lindsey.
Figure 15Hippasteria phrygiana [83]. © Viktor V. Grøtan, some right reserved (CC BY-NC).
Figure 16Narcissia canariensis [89].
Steroidal glycosides that exhibit the highest anticancer activity against various tumor cell lines.
| Compounds | Species | Tumor Cell Lines | Mechanism of Action | IC50 |
|---|---|---|---|---|
| Crude extract |
| Human breast cancer MCF-7 cell lines | Induction of apoptosis | 15.6 µg·mL−1 |
| Plancitoxin I | A375.S2 melanoma cells | Inhibition of cell growth, induction of apoptosis mediated by mitochondrial membrane and p38 pathway | 5.67 µg·mL−1 | |
| Butanol fraction | A375.S2 | Induction of apoptosis and necrosis | 112.65 µg·mL−1 | |
| Anthenoside A |
| human leukemia K-562, hepatoma BEL-7402, glioblastoma U87MG cells | - | |
| Anthenosides B–K | K-562, BEL-7402 cells | - | ||
| Anthenosides J–K |
| human melanoma RPMI-7951, breast adenocarcinoma T-47D, colorectal carcinoma HT-29 | Induction of apoptosis | 89, 91, and 85 µM |
| Archasterosides A |
| human cancer HeLa cells, mouse epidermal JB6 P+ Cl41 cells | - | 24 μM |
| Archasterosides B | human cancer HeLa cells, mouse epidermal JB6 P+ Cl41 cells | Induction of p53- and AP-1-dependent transcriptional | 14 μM | |
| Regularoside A | human cancer HeLa cells, mouse epidermal JB6 P+ Cl41 cells | - | 110 μM | |
| Methanol extract |
| HL-60 leukemia cells, PC-3 prostate cancer cells | Induction of apoptosis via regulation of apoptosis-related proteins and via the down-regulation of ERK1/2 pathway and C-myc | 8.29 µg·mL−1 |
| (20R,24S)-3β,6α,8,15β,24-pentahydroxy-5α-cholestane | HepG2 (hepatoma cancer), KB (epidermoid carcinoma), LNCaP (prostate cancer), MCF7 (breast cancer), SK-Mel2 (melanoma) | - | 18.03–21.59 μM | |
| Methanol extract |
| HL-60, PC-3, SNU-C5 colorectal cancer cells | Induction of apoptosis via the inactivation of PI3K/AKT and ERK 1/2 MAPK pathways and down-regulation of C-myc | 0.84–3.96 µg·mL−1 |
| Cerebrosides (AAC) |
| murine sarcoma cells (S180) | Induction of mitochondria-mediated apoptosis | 216.36 μM |
| Peptides derived from the motifs of cyclin B |
| HCT-116 human colon adenocarcinoma and EC-9706 esophageal carcinoma cells | Induction of apoptosis | 100 μM |
| (25S)-5α-cholestane-3β,4β,6α,7α,8,15β,16β,26-octol | HepG2, | - | 0.2 μM | |
| Fermented | B16F10 murine melanoma cells | Induction of apoptosis | 0.25–0.2 µg·mL−1 | |
| Regularoside A |
| T-47D human breast cancer, RPMI-7951 human malignant melanoma, HCT-116 human colon cancer cells | - | 169, 117, 142 μM |
| Certonardosterols |
| A549, SK-OV-3, SK-MEL-2, XF498, HCT15 | - | - |
| 15-keto sterol | Unspecified | - | - | |
| Certonardoside C | SK-MEL-2 | 3.8 µg·mL−1 | ||
| Certonardosides L | A549 SK-OV-3 SK-MEL-2 XF498 HCT15 | - | 7.5, 6.8, 5.8, 6.4, 3.9 µg·mL−1 | |
| Certonardosides M | A549 SK-OV-3 SK-MEL-2 XF498 HCT15 | - | >30, >30, 9.7, 25.4, 43.4 µg·mL−1 | |
| Certonardosides N | A549 SK-OV-3 SK-MEL-2 XF498 HCT15 | - | 8.0, 8.4, 7.7, 7.2, 8.2 µg·mL−1 | |
| Certonardosides P2 | SK-MEL-2 | - | - | |
| Granulatosides D, Echinasterosides F, desulfated Echinasteroside B Laeviuscoloside D |
| Murine splenocytes | - | 4.7 ± 1.2 |
| Hesperuside A |
| leukemia MOLT-4, hepatoma BEL-7402 | - | 3.62 ± 1.08 |
| Hesperuside B | leukemia MOLT-4, hepatoma BEL-7402 | - | 1.84 ± 0.65 | |
| Hesperuside C | leukemia MOLT-4, hepatoma BEL-7402 | - | 2.40 ± 0.73 | |
| (25S)-5α-cholestane-3β,5,6β,15α,16β,26-hexaol |
| HepG2, U87MG | Inhibition of cell growth and induction of apoptosis | 10–200 μM |
| Asterosaponin 1 |
| U87MG cells | Inhibition of cell growth | 4.3 µg·mL−1 |
| Asterosaponin 1 | K-562, BEL-7402 | - | 3.57 µg·mL−1; | |
| Novaeguinosides A | K-562, BEL-7402 | - | 3.0 ± 0.6, 2.4 ± 0.3 µM | |
| Novaeguinosides B | K-562, BEL-7402 | - | 7.9 ± 1.5, | |
| Novaeguinosides C | K-562, BEL-7402 | - | 1.3 ± 0.2 | |
| Novaeguinosides D | K-562, BEL-7402 | - | 4.6 ± 0.5 | |
| Culcinoside A | human glioblastoma cell lines (U87, U251, and SHG44) | - | 9.35 ± 0.46 11.28 ± 0.65 8.04 ± 0.32µM | |
| Phrygiasterol |
| Ehrlich carcinoma cells | Inhibition of growth | 50 µg·mL−1 |
| Leptasterioside A Leptasterioside B Leptasterioside C |
| T-47D cells | - | 2 |
| Ophidiacerebrosides |
| KMS-11 multiple myeloma, | - | ~20 μM |
| Maculatoside |
| Hep-G2 | - | 16.75 ± 0.69 μM |
Other effects of biological active compounds from starfishes against human cancer cells.
| Compound | Biological Effect |
|---|---|
| CAV (protein toxin from the venom of | Anti-proliferative effect on A375.S2 cell line |
| Acanthaglycoside A | Inhibition of colony formation of HT-29 and MDA-MB-231 cell lines; prevention of the migration of MDA-MB-231 cells |
| Anthenosides A2 | Reduction of T-47D cell colony number |
| Polysaccharides (from | Chemopreventive effect on human colon adenocarcinoma and human breast cancer cells |
| Cariniferoside F, | Inhibition of colony formation of RPMI-7951 and T-47D cell lines |
| Regularoside A | Inhibition of colony formation of HCT-116, RPMI-7951 and |
| Luzonicoside A | Inhibition of proliferation, migration and colony formation of RPMI-7951 and SK-MEL-28 cell lines |
| Hippasterioside D | Reduction of colony number and colony size of HT-29 cells |
| Leptasterioside A | Inhibition of colony formation of T-47D cells |
| Leptaochotensoside A | Reduction of colony formation of T-47D cells |
| Lethasteriosides A | Inhibition of colony formation of T-47D, |